Ozempic and Leg Pain: What STRIDE Actually Showed About Walking Distance

You're walking to the mailbox and your calf seizes up. Not a gym cramp — a tight, burning ache that forces you to stop, wait it out, then start again. If you have type 2 diabetes and that scene sounds familiar, the symptom has a name, and there's a trial people have suddenly started quoting at each other.

The trial is called STRIDE, and it's one of the rare large trials built to look squarely at walking ability in PAD: can a GLP-1 shot most people know as a diabetes or weight drug actually help you walk farther when peripheral artery disease is choking the blood flow to your legs? Short version — it nudged walking distance up by about 13% over a year. The longer version is the one worth your time, because it's really about three things: who that 13% applies to, what the number doesn't prove, and why a good doctor will hand you a careful answer instead of a headline.

First, what's going on in your legs

Peripheral artery disease — PAD — is plaque building up in the arteries that feed your legs. Less blood gets through. When you walk, the muscle demands more oxygen than the narrowed pipes can deliver, and the muscle protests. That protest is the cramping, aching, or fatigue doctors call intermittent claudication. It shows up with exertion and eases when you rest, which is the tell that separates it from a random pulled muscle.

The people in STRIDE were at what doctors label Fontaine stage IIa: symptomatic, limited by the pain, but not yet at the rest-pain or tissue-loss stage. In plain terms, they could walk — just not far, and the distance was the thing wrecking their day. PAD also travels with company. The same plaque process tends to surface in the heart and elsewhere, which is why a leg symptom is rarely just a leg symptom.

Diabetes makes all of it worse. Years of high blood sugar damage the vessels and the nerves, so people with type 2 diabetes tend to develop PAD earlier, feel it differently, and have a harder time with it. That overlap is exactly the population STRIDE went after.

What STRIDE set out to test

Here's the setup. STRIDE was a phase 3b trial — double-blind, randomized, and placebo-controlled, run across 112 outpatient sites in 20 countries spanning North America, Asia, and Europe. That's a serious footprint, not a single-clinic pilot you can wave off.

Researchers enrolled 792 people, all with symptomatic PAD and type 2 diabetes, and split them down the middle: 396 got semaglutide, 396 got placebo. The semaglutide group took a once-weekly 1.0 mg subcutaneous injection — the shot — for 52 weeks. Neither the participants nor the people measuring outcomes knew who got what. That's the entire point of a double-blind design: it keeps wishful thinking out of the data.

This group was older and stacked with risk. Median age was 68. Median diabetes duration was 12 years. More than a quarter were current smokers, almost 88% had high blood pressure, and roughly 43% already had coronary heart disease. These weren't lightly affected volunteers. They were the patients a vascular clinic sees every week.

The design matters here. A double-blind, placebo-controlled trial across 20 countries is the kind of evidence that moves a conversation forward — rather than another small open-label study that leaves everyone arguing.

And the thing they measured was deliberately concrete: walking distance on a treadmill.

The number everyone's quoting: about 13%

The primary endpoint was the ratio to baseline of maximum walking distance at week 52, measured on a constant-load treadmill. Translation: they put people on a treadmill set to a steady pace, recorded how far each one could walk before pain stopped them, repeated it a year later, and compared the change in the semaglutide group against the change in placebo.

Here's where it landed. The estimated treatment ratio was 1.13, with a 95% confidence interval of 1.06 to 1.21, and a p-value of 0.0004. That ratio of 1.13 is the headline: people on semaglutide walked about 13% farther than they would have on placebo. Broken out by arm, the median ratio was 1.21 with semaglutide versus 1.08 with placebo.

Two things are worth pulling out of that table. The confidence interval sits entirely above 1.0, so the benefit wasn't a statistical coin flip. And a p-value of 0.0004 means the result is very unlikely to be noise. This is a real signal, reported in the STRIDE trial, not a press-release flourish.

So how big is 13%, really?

This is the part where the skeptic deserves a straight answer. Thirteen percent is a meaningful functional gain. It is not a cure. The gap between those two ideas is the whole story.

Think about what walking distance does for someone with claudication. If pain currently stops you halfway down the block, a little more distance can be the difference between reaching the bus stop and turning back. The trial reported the change as a ratio rather than a fixed number of extra meters, so the practical payoff scales with where you started. The point is mobility and daily life, not a number to brag about.

Now the restraint. Thirteen percent farther on a treadmill is an improvement in function — how far you can walk before pain. It is not proof that the arteries reopened, that plaque cleared, or that the underlying disease reversed. A treadmill test measures what your legs can do. It does not photograph your blood vessels. Holding those two apart is the difference between an honest read and hype.

Why might a GLP-1 help the legs at all?

Fair question, and the truthful answer is that nobody fully knows yet. A few candidates are plausible.

• Weight loss. GLP-1 medications reduce body weight, and carrying less load could make walking easier on a strained system.
• Blood sugar. Better glucose control over time is gentler on the small vessels and nerves that diabetes chews up.
• Inflammation. GLP-1 drugs appear to have anti-inflammatory effects, and arterial disease is partly an inflammatory process.

Here's the catch: STRIDE measured the outcome, not the mechanism. It showed walking distance went up. It did not prove which of those levers — or which combination — did the work. The trial's own authors flagged that future studies are needed to clarify how the effect happens. When a careful research team says it doesn't know the mechanism yet, the responsible move is to repeat that, not to fill the gap with a tidy story.

Semaglutide increased walking distance in people with symptomatic PAD and type 2 diabetes. That's the finding. The "why" is still an open question the researchers themselves want answered.

The fine print that decides who this is for

Read this section twice. It's where confident headlines go wrong.

Every person in STRIDE had type 2 diabetes. The trial enrolled people with PAD and diabetes, full stop, so the result speaks to that specific overlap. Whether semaglutide helps walking distance in someone who has PAD but not diabetes is genuinely unknown — and the trial authors said as much, noting that people with PAD who don't have type 2 diabetes still need to be studied. If you have PAD with normal blood sugar, STRIDE is interesting context, not a result about you.

Then there's the regulatory reality, which trips up a lot of conversations. Semaglutide is sold as Ozempic for type 2 diabetes; the higher-dose version, Wegovy, is approved for weight management. Neither is approved as a treatment for peripheral artery disease — no regulator has cleared it for that use. STRIDE is evidence, and strong evidence at that — its primary results were published in The Lancet in 2025 — but evidence is not the same thing as an approved indication.

Put those rows together and you get the right frame: a promising, well-run result in one defined group, not a green light for everyone with leg pain.

What about side effects?

No medication is free, so this deserves a clear-eyed look. Inside STRIDE, serious treatment-related adverse events were uncommon — five participants (1%) on semaglutide and six (2%) on placebo — and the serious ones that did show up were most often gastrointestinal. There were no treatment-related deaths in the trial.

In everyday use, the most common reactions to semaglutide are gut-related: nausea, vomiting, diarrhea, abdominal pain, and constipation. They tend to be worst when starting or stepping up a dose, and they usually settle as the body adjusts. None of that makes the medication risk-free, and a couple of warnings sit at a different level of seriousness entirely.

Two are worth knowing by name. Semaglutide carries a boxed warning about thyroid C-cell tumors and is contraindicated — off the table — for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Separately, acute pancreatitis has been reported; if it's suspected, the medication should be stopped promptly. These aren't "side effects to ride out." They're reasons a particular person may not be a candidate at all — exactly the kind of thing a prescriber screens for.

If you have PAD, where does this leave you?

Somewhere useful, as long as you keep the trial's limits in view.

If you already take Ozempic for diabetes and you also have claudication, STRIDE is a genuine reason to feel cautiously encouraged. You're close to the population that was studied. But the shot wasn't doing this work alone — the people in the trial were managing the rest of their disease, too. The proven backbone of PAD care hasn't changed:

• Supervised exercise therapy — structured walking programs remain a first-line, evidence-backed way to extend pain-free distance.
• Smoking cessation — nothing else moves the needle on PAD as hard as quitting, and a quarter of the trial participants still smoked.
• Managing the rest — blood pressure, cholesterol, and blood sugar control all protect the same vessels.

If you don't have diabetes, the truthful takeaway is patience. The signal is interesting, but it wasn't tested in you, and good clinicians don't extrapolate across a gap the researchers explicitly flagged. The move isn't to chase a prescription off a headline. It's to keep doing the things with strong evidence behind them and watch this space, because follow-up studies are coming.

Questions worth bringing to your doctor

You don't need to memorize the trial to have a good conversation. A few plain questions go a long way:

• Given my specific situation — diabetes or not, how far I can walk, my other conditions — does any of the STRIDE evidence apply to me?
• Am I already on the proven PAD basics: a supervised walking program, smoking cessation support, and good control of blood pressure and cholesterol?
• If I'm on a GLP-1 already, or weighing one for diabetes, what should I realistically expect for my legs versus my blood sugar?
• Are there reasons — a thyroid cancer history, a past bout of pancreatitis — that would take semaglutide off the table for me?

The best version of this conversation isn't "I read about a drug, give me the drug." It's "here's a new piece of evidence — does it change anything for someone like me?" That second question is the one a good doctor can actually answer.

STRIDE is a real result, and a careful one: in people who had both symptomatic PAD and type 2 diabetes, semaglutide added about 13% to walking distance over 52 weeks. It isn't a cure, it isn't approved for PAD, and it wasn't tested in people without diabetes — and the researchers were the first to say so. All of it comes from published clinical-trial and peer-reviewed data, and what any of it means for your own legs is a question to work through with the doctor who knows your history.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app